Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, both GRN and TMEM106B have already been associated with neuropathological features of AD46–48.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058 · cited 1×
“Initial papers observed features of PGRN immunoreactivity in microglia around senile plaques in AD cases when comparison was being made with neuropathological features of FTLD due to GRN mutations [13,127].”
ResultElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundTang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761 · cited 2×
“It had been speculated that if PGRN could function by blocking TNF-α activation, it would provide a rationale for the use of PGRN in diseases involving excess TNF-α including RA [95].”
BackgroundLui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729 · cited 7×
“Increased numbers of activated microglia and C1qa immunoreactivity were also observed in human FTLD GRN mutation carriers but not in AD cases [10].”
BackgroundResultInfluentialSpangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Conversion of Proepithelin to Epithelins
Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Wright, C. D., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01141-8 · Cited by 633 · cited 1×
“PGRN cleavage is prevented by secretory leukocyte protease inhibitor (SLPI), which binds directly to PGRN linker sequences [49].”
Background
Cited by
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Advancing cell therapy for neurodegenerative diseases
Temple, S. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.03.017 · Cited by 198
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Cell type-specific inference of differential expression in spatial transcriptomics
Cable, D. M., Murray, E., Shanmugam, V., Zhang, S., Zou, L. S., Diao, M., Chen, H., Macosko, E. Z., Irizarry, R. A., & Chen, F. (2022) · Nature Methods · doi:10.1038/s41592-022-01575-3 · Cited by 164
“…anti-inflammatory gene Grn was upregulated in microglia near plaque (log 2 fold-change 0.79, P = 6 × 10 − 4 ), consistent with previous knowledge 40 . progenitors create radial projections out from the hypothalamic midline, which are used as scaffolds for the migration of differentiating…”
BackgroundResultInfluentialCano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“Progranulin, a glycoprotein mainly secreted by activated microglia, is involved in the modulation of neuroinflammation [73].”
Background
Metadata
- Authors
- Mendsaikhan, A., Tooyama, I., & Walker, D. G.
- Affiliations
- Shiga University of Medical Science (JP)
- Corresponding author
- Mendsaikhan, Anarmaa
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-03-11
- Volume
- 8
- Issue
- 3
- Pages
- 230
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6468562
- OpenAlex
- W2920995467
- Cited by
- 72
- References
- 159
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 12 · 2020: 6 · 2019: 3
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (26290022)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- progranulin, microglia, Alzheimer's disease, neurodegenerative diseases, frontotemporal lobar degeneration, neuronal ceroid lipofuscinosis, lysosomal dysfunction, neuroinflammation, anti-inflammatory activity, neurotrophic factors
- MeSH terms
- Progranulins, Alzheimer Disease, Animals, Disease Models, Animal, Humans, Lysosomes, Microglia, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/cells8030230
- The paper
- Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019). Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases. Cells. https://doi.org/10.3390/cells8030230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.